Dr Salmon then joined the Merad laboratory and learned about myeloid cell biology to develop immunotherapeutic strategies modulating this cell compartment in solid tumors to enhance clinical response to existing therapies. She showed that the paucity of activated CD103+ dendritic cells (DCs) in tumors limits checkpoint blockade efficacy. Expansion and activation of CD103+ DC progenitors at the tumor site promote T cell activation and entry into the tumor, improving tumor response to PD-L1 inhibition (Immunity 2016).
Taking advantage of her expertise in cell dynamics and the tumor microenvironment, Dr Hélène Salmon has started a research program focused on the understanding of stroma contribution to tumor immunity.
Anti-Tumor Therapy, Dendritic Cells, Imaging, Immunology, T Cells, Trafficking, Translational Research
Master, Ecole Normale Supérieure
PhD, Paris-Descartes University (Paris V)
Robin Chemers Neustein Award
Award for women scientists who demonstrated high-impact accomplishments in the biomedical sciences and the potential for an independent scientific career
Cancer Research Institute (CRI) Irvington Postdoctoral Fellowship
Association pour la Recherche sur le Cancer (ARC) Postdoctoral Fellowship
Ph.D. Thesis Prize
Cochin Institute, Paris
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Palucka A, Brown B, Brody J, Ginhoux F, Merad M. Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity 2016;.
Price J, Idoyaga J, Salmon H, Hogstad B, Bagarella C, Ghaffari S, Leboeuf M, Merad M. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nature Immunology 2015;.
Merad M, Salmon H. Cancer: A dendritic-cell brake on antitumour immunity. Nature 2015;.
Reuter E, Gollan R, Grohmann N, Paterka M, Salmon H, Birkenstock J, Richers S, Leuenberger T, Brandt A, Kuhlmann T, Zipp F, Siffrin V. Cross-recognition of a myelin peptide by CD8+ T cells in the CNS is not sufficient to promote neuronal damage. Journal of Neuroscience 2015;.
Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Leboeuf M, Beltrao M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine 2014;.
Agudo J, Ruzo A, Tung N, Salmon H, Leboeuf M, Hashimoto D, Becker C, Garrett-Sinha LA, Baccarini A, Merad M, Brown BD. The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nature Immunology 2014;.
Peranzoni E, Rivas-Caicedo A, Bougherara H, Salmon H, Donnadieu E. Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Molecular Life Sciences 2013;.
Salmon H, Donnadieu E. Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix. Oncoimmunology 2012;.
Salmon H, Donnadieu E. The extracellular matrix: an obstacle to T cell-tumor cell interaction [review]. Medecine Sciences 2012;.
Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean M, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. Journal of Clinical Investigation 2012;.
Salmon H, Rivas-Caicedo A, Asperti-Boursin F, Lebugle C, Bourdoncle P, Donnadieu E. Ex vivo imaging of T cells in murine lymph node slices with widefield and confocal microscopes. Journal of Visualized Experiments 2011;.
Wang SF, Fouquet S, Chapon M, Salmon H, Régnier F, Damotte D, Validire P, Maubec E, Dieu-Nosjean M, Zerbib M, Avril M, Prévost-Blondel A, Randriamampita C, Trautmann A, Bercovici N. Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One 2011;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Salmon did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.